GlassScriptPhysician profile
Andrew Patterson
NPI 1518387901
$2,678.83
in general payments reported to CMS, 2019-2025
26 companies · $906 in 2025
The $906 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $138 · 2021: $65.98 · 2022: $266 · 2023: $543 · 2024: $616 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,065.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $363.63 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $357.72 | 2020-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $269.71 | 2024-2025 | |
| Amgen INC. | $257.71 | 2021-2024 | Repatha |
| Merck Sharp & Dohme LLC | $251.49 | 2022-2025 | Verquvo |
| Scpharmaceuticals INC. | $184.02 | 2025 | |
| Novo Nordisk INC | $162.94 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $148.29 | 2023-2025 | Brilinta, Bevespi Aerosphere, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.41 | 2023-2025 | Jardiance |
| Lantheus Medical Imaging, INC. | $83.69 | 2019-2025 | |
| Medtronic, INC. | $69.54 | 2025 | Hawkone |
| Abbott Laboratories | $66.19 | 2019-2024 | Mitraclip |
| Kiniksa Pharmaceuticals International, Plc | $64.68 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $38.24 | 2025 | Attruby |
| Atricure, INC. | $33.46 | 2023-2025 | Synergy Ablation System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $28.47 | 2019 | |
| Zoll Respicardia, INC. | $25.73 | 2023 | Remede System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.46 | 2023 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $23.39 | 2024 | |
| Esperion Therapeutics, INC. | $20.46 | 2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $18.83 | 2024 | |
| Lilly USA, LLC | $18.51 | 2025 | Zepbound |
| Heartflow, INC. | $18.14 | 2023 | Ffrct |
| Janssen Pharmaceuticals, INC | $16.96 | 2023 | Xarelto |
| Impulse Dynamics (USA) INC. | $16.91 | 2024 | Optimizer |
| Terumo Medical Corporation | $16.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.